Evidence map›Paper›PMID 31955362›Full record

ReviewInternational urology and nephrology2020

Dialysis-associated hyperglycemia: manifestations and treatment.

Yijuan Sun, Maria-Eleni Roumelioti, Kavitha Ganta, Robert H Glew, James Gibb, Darlene Vigil, Catherine Do, Karen S Servilla, Brent Wagner, Jonathan Owen and 4 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in International urology and nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yijuan SunRenal Section, Medicine Service, Raymond G. Murphy Veterans Affairs Medical Center, 1501 San Pedro, SE, Albuquerque, NM, 87108, USA.ORCID http://orcid.org/0000-0001-6172-1360
Maria-Eleni RoumeliotiDivision of Nephrology, Department of Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.ORCID http://orcid.org/0000-0003-0724-5767
Kavitha GantaRenal Section, Medicine Service, Raymond G. Murphy Veterans Affairs Medical Center, 1501 San Pedro, SE, Albuquerque, NM, 87108, USA.ORCID http://orcid.org/0000-0001-5146-1067
Robert H GlewDepartment of Surgery, University of New Mexico School of Medicine, Albuquerque, NM, USA.ORCID http://orcid.org/0000-0003-2453-4771
James GibbDivision of Nephrology, Department of Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.ORCID http://orcid.org/0000-0002-8495-712X
Darlene VigilRenal Section, Medicine Service, Raymond G. Murphy Veterans Affairs Medical Center, 1501 San Pedro, SE, Albuquerque, NM, 87108, USA.ORCID http://orcid.org/0000-0001-8227-2808
Catherine DoRenal Section, Medicine Service, Raymond G. Murphy Veterans Affairs Medical Center, 1501 San Pedro, SE, Albuquerque, NM, 87108, USA.ORCID http://orcid.org/0000-0002-9688-1820
Karen S ServillaRenal Section, Medicine Service, Raymond G. Murphy Veterans Affairs Medical Center, 1501 San Pedro, SE, Albuquerque, NM, 87108, USA.ORCID http://orcid.org/0000-0002-2255-2231
Brent WagnerRenal Section, Medicine Service, Raymond G. Murphy Veterans Affairs Medical Center, 1501 San Pedro, SE, Albuquerque, NM, 87108, USA.ORCID http://orcid.org/0000-0002-7063-0142
Jonathan OwenDivision of Nephrology, Department of Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.ORCID http://orcid.org/0000-0003-2187-4957
Mark RohrscheibDivision of Nephrology, Department of Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.ORCID https://orcid.org/0000-0001-6340-4166
Richard I DorinEndocrinology Section, Raymond G. Murphy Veterans Affairs Medical Section, and Division of Endocrinology, University of New Mexico School of Medicine, Albuquerque, NM, USA.ORCID http://orcid.org/0000-0002-2402-8054
Glen H MurataPhysician, Raymond G. Murphy Veterans Affairs Medical Center, Albuquerque, NM, USA.ORCID http://orcid.org/0000-0001-8067-8281
Antonios H TzamaloukasRenal Section, Medicine Service, Raymond G. Murphy Veterans Affairs Medical Center, 1501 San Pedro, SE, Albuquerque, NM, 87108, USA. Antonios.Tzamaloukas@va.gov.ORCID http://orcid.org/0000-0002-7170-3323

Funding

Chemokine Receptors in MRI Contrast-Induced Organ FibrosisR01DK102085 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI WAGNER, BRENT · 2014 to 2017
$1.2M
Fibrocyte Contribution to Systemic Fibrosis in Chronic Kidney DiseaseI01BX001958 · VA · SOUTH TEXAS VETERANS HEALTH CARE SYSTEM · PI WAGNER, BRENT · 2014 to 2017
–
BLRD VA I01 BX001958NIDDK NIH HHS R01 DK102085
6 · The paper itself

Abstract

purposeDialysis-associated hyperglycemia (DAH), is associated with a distinct fluid and electrolyte pathophysiology. The purpose of this report was to review the pathophysiology and provide treatment guidelines for DAH.

methodsReview of published reports on DAH. Synthesis of guidelines based on these reports.

resultsThe following fluid and solute abnormalities have been identified in DAH: (a) hypoglycemia: this is a frequent complication of insulin treatment and its prevention requires special attention. (b) Elevated serum tonicity. The degree of hypertonicity in DAH is lower than in similar levels of hyperglycemia in patients with preserved renal function. Typically, correction of hyperglycemia with insulin corrects the hypertonicity of DAH. (c) Extracellular volume abnormalities ranging from pulmonary edema associated with osmotic fluid shift from the intracellular into the extracellular compartment as a consequence of gain in extracellular solute (glucose) to hypovolemia from osmotic diuresis in patients with residual renal function or from fluid losses through extrarenal routes. Correction of DAH by insulin infusion reverses the osmotic fluid transfer between the intracellular and extracellular compartments and corrects the pulmonary edema, but can worsen the manifestations of hypovolemia, which require saline infusion. (d) A variety of acid-base disorders including ketoacidosis correctable with insulin infusion and no other interventions. (e) Hyperkalemia, which is frequent in DAH and is more severe when ketoacidosis is also present. Insulin infusion corrects the hyperkalemia. Extreme hyperkalemia at presentation or hypokalemia developing during insulin infusion require additional measures.

conclusionsIn DAH, insulin infusion is the primary management strategy and corrects the fluid and electrolyte abnormalities. Patients treated for DAH should be monitored for the development of hypoglycemia or fluid and electrolyte abnormalities that may require additional treatments.

Indexed as

HyperglycemiaKidney Failure, ChronicRenal DialysisHumansPatient Care ManagementWater-Electrolyte ImbalanceAcid–base disturbancesHyperglycemiaHyperkalemiaHypertonicityMaintenance dialysisPulmonary edema

Identifiers

PMID31955362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.